AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16517331 — intervention group
Group type: COMPARATOR
Intervention: Group I (control) - preoperative placebo tablet, thiopental induction, isoflurane-N2O maintenance
Number of subjects: 150
Study 12802713 — intervention group
Group type: EXPERIMENTAL
Intervention: High risk of perinatal infection (n=8)
Number of subjects: 166
Study 12802713 — intervention group
Group type: COMPARATOR
Intervention: Healthy newborns (n=59)
Number of subjects: 166
Study 12802713 — intervention group
Group type: COMPARATOR
Intervention: Low risk of perinatal infection (n=18)
Number of subjects: 166
Study 12802713 — intervention group
Group type: EXPERIMENTAL
Intervention: High risk of perinatal infection (n=20) in 37 to 72-hour subgroup
Number of subjects: 166
Study 12802713 — intervention group
Group type: COMPARATOR
Intervention: Healthy newborns (n=49) in 37 to 72-hour subgroup
Number of subjects: 166
Study 12802713 — intervention group
Group type: COMPARATOR
Intervention: Low risk of perinatal infection (n=12) in 37 to 72-hour subgroup
Number of subjects: 166
Study 11019880 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracey Technology wavefront device
Number of subjects: 9
Study 11019880 — intervention group
Group type: COMPARATOR
Intervention: Conventional videokeratoscopes
Number of subjects: 9
Study 8888927 — intervention group
Group type: EXPERIMENTAL
Intervention: Early physiotherapy
Number of subjects: 105
Study 8888927 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (delaying physiotherapy until abnormal physical signs became apparent)
Number of subjects: 105
Study 1507376 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based interview
Number of subjects: 294
Study 1507376 — intervention group
Group type: COMPARATOR
Intervention: Standard Red Cross procedure
Number of subjects: 294
Study 6367929 — intervention group
Group type: EXPERIMENTAL
Intervention: Alza T IPCS 52
Number of subjects: 5542
Study 6367929 — intervention group
Group type: COMPARATOR
Intervention: TCu22OC
Number of subjects: 5542
Study 6367929 — intervention group
Group type: COMPARATOR
Intervention: Multiload 250
Number of subjects: 5542
Study 30896976 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard IKDC‐SKF
Number of subjects: 100
Study 30896976 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved R/L IKDC‐SKF
Number of subjects: 100
Study 30896976 — intervention group
Group type: EXPERIMENTAL
Intervention: R/L IKDC‐SKF
Number of subjects: 100
Study 29167485 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Deprivation (SD)
Number of subjects: 0
Study 27485060 — intervention group
Group type: EXPERIMENTAL
Intervention: Rowachol 100 mg orally three times daily for 3 months after surgery
Number of subjects: 138
Study 27485060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 24976083 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-transfer patients
Number of subjects: 9204
Study 24976083 — intervention group
Group type: COMPARATOR
Intervention: Transferred patients
Number of subjects: 9204
Study 21680781 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin 500 mg once a day for 13 days
Number of subjects: 18
Study 19301734 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous integrated boost (10 Gy/25F)
Number of subjects: 60
Study 19301734 — intervention group
Group type: COMPARATOR
Intervention: Sequential boost (15 Gy/5F)
Number of subjects: 60
Study 17461530 — intervention group
Group type: EXPERIMENTAL
Intervention: 40mL of 300mg ropivacaine with 1:200,000 epinephrine and 5mg morphine
Number of subjects: 90
Study 17461530 — intervention group
Group type: EXPERIMENTAL
Intervention: 40mL of 300mg ropivacaine with epinephrine
Number of subjects: 90
Study 17461530 — intervention group
Group type: COMPARATOR
Intervention: 50mL normal saline (control)
Number of subjects: 90
Study 17461530 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90
Study 15200445 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate 50 mg administered 2 hours before hemodialysis
Number of subjects: 15
Study 15200445 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate 50 mg administered 2 hours after hemodialysis
Number of subjects: 15
Study 15200445 — intervention group
Group type: COMPARATOR
Intervention: Control (no sildenafil)
Number of subjects: 15
Study 12473004 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol 50 mg bid or 100 mg bid for 12, 16, or 24 weeks
Number of subjects: 1751
Study 12473004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1751
Study 11440349 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine (TGB), dosage up to 64 mg/day
Number of subjects: 88
Study 11440349 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine (TGB)
Number of subjects: 88
Study 11440349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 9402169 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (50 mg/m2), Epirubicin (70 mg/m2), Paclitaxel (175 mg/m2 over three hours)
Number of subjects: 49
Study 9402169 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin, Epirubicin, and Paclitaxel (CEP) regimen
Number of subjects: 49
Study 8500917 — intervention group
Group type: EXPERIMENTAL
Intervention: ITF 282 (60 mg iron once daily for children ≤40 kg; twice daily for children >40 kg)
Number of subjects: 502
Study 8500917 — intervention group
Group type: COMPARATOR
Intervention: Ferrous polystyrene sulphonate (52.5 mg iron once daily for children ≤40 kg; twice daily for children >40 kg)
Number of subjects: 502
Study 8500917 — intervention group
Group type: EXPERIMENTAL
Intervention: ITF 282
Number of subjects: 502
Study 8500917 — intervention group
Group type: COMPARATOR
Intervention: Ferrous polystyrene sulphonate
Number of subjects: 502
Study 3319629 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training plus individual relaxation and breathing therapy (treatment A)
Number of subjects: 90
Study 3319629 — intervention group
Group type: COMPARATOR
Intervention: Exercise training only (treatment B)
Number of subjects: 90
Study 29196816 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing nursing care
Number of subjects: 74
Study 29196816 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing care
Number of subjects: 74
Study 28090293 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral treprostinil (up-titrated from 0.25 mg twice daily)
Number of subjects: 310
Study 28090293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study 24128818 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based program ('ESS-KIMO') consisting of six online MET sessions
Number of subjects: 212
Study 24128818 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control condition
Number of subjects: 212
Study 22084312 — intervention group
Group type: EXPERIMENTAL
Intervention: Carriers of the -1377A variant of the CD95 gene
Number of subjects: 231
Study 20450357 — intervention group
Group type: EXPERIMENTAL
Intervention: mod SLA implants
Number of subjects: 39
Study 20450357 — intervention group
Group type: COMPARATOR
Intervention: historic control group with SLA surface
Number of subjects: 39
Study 16189077 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 2.0-g oral dose of azithromycin microspheres (n = 213)
Number of subjects: 427
Study 16189077 — intervention group
Group type: COMPARATOR
Intervention: 7-day regimen of levofloxacin (500 mg/day) (n = 214)
Number of subjects: 427
Study 12549813 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person counseling
Number of subjects: 652
Study 12549813 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person counseling and physician's letter intervention
Number of subjects: 652
Study 12549813 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone contact and physician's letter combination
Number of subjects: 652
Study 12549813 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician's letter
Number of subjects: 652
Study 12549813 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person counseling and physician's letter combination
Number of subjects: 652
Study 12549813 — intervention group
Group type: COMPARATOR
Intervention: All 5 interventions
Number of subjects: 652
Study 10381107 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium mupirocin ointment
Number of subjects: 267
Study 10381107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study 8873694 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide (20 mg by mouth t.i.d.)
Number of subjects: 20
Study 8873694 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (20 mg by mouth t.i.d.)
Number of subjects: 20
Study 1998848 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg stanozolol intramuscularly 24 hours before operation, followed by 5 mg stanozolol orally twice daily for 6 weeks
Number of subjects: 27
Study 1998848 — intervention group
Group type: COMPARATOR
Intervention: Placebo intramuscularly 24 hours before operation, followed by placebo orally twice daily for 6 weeks
Number of subjects: 27
Study 1998848 — intervention group
Group type: EXPERIMENTAL
Intervention: Stanozolol
Number of subjects: 27
Study 28726810 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone disclosure of genetic test results
Number of subjects: 257
Study 28726810 — intervention group
Group type: COMPARATOR
Intervention: In-person disclosure of genetic test results
Number of subjects: 257
Study 27316679 — intervention group
Group type: EXPERIMENTAL
Intervention: Yirui capsule
Number of subjects: 0
Study 27316679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24733515 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped collaborative care intervention including motivational interviewing, medication, and cognitive behavioral therapy targeting PTSD and depressive symptoms.
Number of subjects: 120
Study 24733515 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care).
Number of subjects: 120
Study 22214752 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg)
Number of subjects: 18
Study 22214752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 20463564 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood injection
Number of subjects: 60
Study 20463564 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injection (methylprednisolone)
Number of subjects: 60
Study 17522603 — intervention group
Group type: EXPERIMENTAL
Intervention: High calcium-high vitamin D breakfast (HCB)
Number of subjects: 8
Study 17522603 — intervention group
Group type: COMPARATOR
Intervention: Low calcium-low vitamin D breakfast
Number of subjects: 8
Study 17522603 — intervention group
Group type: COMPARATOR
Intervention: Both lunches (after HCB and low calcium-low vitamin D breakfast)
Number of subjects: 8
Study 16782910 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV chemotherapy plus radiotherapy (RT), n = 147
Number of subjects: 289
Study 16782910 — intervention group
Group type: COMPARATOR
Intervention: RT alone, n = 142
Number of subjects: 289
Study 16782910 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV plus RT
Number of subjects: 289
Study 16782910 — intervention group
Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 289
Study 16782910 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with tumors lacking 1p and 19q
Number of subjects: 289
Study 16782910 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with tumors not lacking 1p and 19q
Number of subjects: 289
Study 14567804 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin depot 11.25 mg 3 months before surgery (group A)
Number of subjects: 62
Study 14567804 — intervention group
Group type: COMPARATOR
Intervention: No treatment (group B)
Number of subjects: 62
Study 10751862 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone and prednisone
Number of subjects: 133
Study 9096431 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (40 mg/day) for 1 month
Number of subjects: 32
Study 9096431 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 32
Study 9096431 — intervention group
Group type: COMPARATOR
Intervention: Cirrhosis Child A
Number of subjects: 32
Study 9096431 — intervention group
Group type: COMPARATOR
Intervention: Cirrhosis Child C
Number of subjects: 32
Study 8472118 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated radiotherapy
Number of subjects: 1345
Study 8472118 — intervention group
Group type: EXPERIMENTAL
Intervention: T3 tumours
Number of subjects: 1345
Study 8472118 — intervention group
Group type: EXPERIMENTAL
Intervention: T2 tumours
Number of subjects: 1345
Study 8472118 — intervention group
Group type: EXPERIMENTAL
Intervention: T1 tumours
Number of subjects: 1345
Study 8472118 — intervention group
Group type: EXPERIMENTAL
Intervention: Time component
Number of subjects: 1345
Study 2422744 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 20
Study 2422744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29850858 — intervention group
Group type: EXPERIMENTAL
Intervention: General domain (n = 58)
Number of subjects: 234
Study 29850858 — intervention group
Group type: EXPERIMENTAL
Intervention: Health domain (n = 60)
Number of subjects: 234
Study 29850858 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral domain (n = 56)
Number of subjects: 234
Study 29850858 — intervention group
Group type: EXPERIMENTAL
Intervention: TACT domain (n = 60)
Number of subjects: 234
Study 30246666 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 1120
Study 26508298 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (400 µg/day)
Number of subjects: 159
Study 26508298 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 159
Study 25360652 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (intravenous)
Number of subjects: 40
Study 25360652 — intervention group
Group type: COMPARATOR
Intervention: Control (natural saline)
Number of subjects: 40
Study 22119318 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (CS less painful)
Number of subjects: 48
Study 22119318 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocebo (CS more painful)
Number of subjects: 48
Study 22119318 — intervention group
Group type: COMPARATOR
Intervention: Informed control for placebo group
Number of subjects: 48
Study 22119318 — intervention group
Group type: COMPARATOR
Intervention: Informed control for nocebo group
Number of subjects: 48
Study 19660461 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting and postprandial colonic tone and compliance in chronic constipation (NTC, STC, DD-normal, DD-slow)
Number of subjects: 146
Study 19660461 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance in isolated STC and DD
Number of subjects: 146
Study 19660461 — intervention group
Group type: EXPERIMENTAL
Intervention: Principal components analysis of colonic motor parameters
Number of subjects: 146
Study 18563972 — intervention group
Group type: EXPERIMENTAL
Intervention: music‐assisted progressive muscle relaxation (PMR) and imagery group (n = 15)
Number of subjects: 30
Study 18563972 — intervention group
Group type: EXPERIMENTAL
Intervention: improvisation‐assisted desensitization group (n = 15)
Number of subjects: 30
Study 18563972 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 30
Study 16105282 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based distribution (CBD)
Number of subjects: 297
Study 11961025 — intervention group
Group type: EXPERIMENTAL
Intervention: Stop CsA
Number of subjects: 212
Study 11961025 — intervention group
Group type: EXPERIMENTAL
Intervention: Stop Pred
Number of subjects: 212
Study 11961025 — intervention group
Group type: COMPARATOR
Intervention: Continue triple drug therapy (Control)
Number of subjects: 212
Study 10389350 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic imaging
Number of subjects: 15
Study 10389350 — intervention group
Group type: COMPARATOR
Intervention: Conventional imaging
Number of subjects: 15
Study 10389350 — intervention group
Group type: COMPARATOR
Intervention: Fundamental imaging
Number of subjects: 15
Study 10389350 — intervention group
Group type: EXPERIMENTAL
Intervention: Second harmonic imaging
Number of subjects: 15
Study 7553634 — intervention group
Group type: EXPERIMENTAL
Intervention: 2B1 at 1.0 mg/m2
Number of subjects: 15
Study 7553634 — intervention group
Group type: EXPERIMENTAL
Intervention: 2B1 at 2.5 mg/m2
Number of subjects: 15
Study 7553634 — intervention group
Group type: EXPERIMENTAL
Intervention: 2B1 at 5.0 mg/m2
Number of subjects: 15
Study 7553634 — intervention group
Group type: EXPERIMENTAL
Intervention: 2B1 (all doses)
Number of subjects: 15
Study 2183632 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous caffeine pretreatment
Number of subjects: 40
Study 2183632 — intervention group
Group type: COMPARATOR
Intervention: Electrical stimulus intensity dosing
Number of subjects: 40
Study 2183632 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 40
Study 2183632 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine pretreatment
Number of subjects: 40
Study 7392905 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg of Dexedrine per 70 kg of body weight
Number of subjects: 6
Study 7392905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31372757 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (100 mcg/day)
Number of subjects: 12
Study 31372757 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 12
Study 31029692 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition Care Coordinator Care (TCC Care) - Full intervention (delivered in-hospital and by post-discharge phone call)
Number of subjects: 7038
Study 31029692 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition Care Coordinator Care (TCC Care) - Partial intervention (phone call only)
Number of subjects: 7038
Study 31029692 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 7038
Study 28815410 — intervention group
Group type: EXPERIMENTAL
Intervention: 4F-PCC (Beriplex®/Kcentra®)
Number of subjects: 11
Study 25433202 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS-guided everolimus-eluting stent implantation
Number of subjects: 1400
Study 25433202 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided everolimus-eluting stent implantation
Number of subjects: 1400
Study 23452523 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to personal choice of music for 30 minutes
Number of subjects: 87
Study 23452523 — intervention group
Group type: COMPARATOR
Intervention: Control group (rest in bed)
Number of subjects: 87
Study 21747085 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrecolomab (five infusions at 28-day intervals)
Number of subjects: 1738
Study 21747085 — intervention group
Group type: COMPARATOR
Intervention: Observation without adjuvant therapy
Number of subjects: 1738
Study 19267710 — intervention group
Group type: EXPERIMENTAL
Intervention: New insulin treatment (group III, n = 245)
Number of subjects: 865
Study 19267710 — intervention group
Group type: COMPARATOR
Intervention: Insulin before inclusion continued during the first year of follow up (group IV, n = 271)
Number of subjects: 865
Study 19267710 — intervention group
Group type: COMPARATOR
Intervention: Lowest quartile of body weight increase
Number of subjects: 865
Study 19267710 — intervention group
Group type: COMPARATOR
Intervention: Each kilogram increase in weight
Number of subjects: 865
Study 19267710 — intervention group
Group type: COMPARATOR
Intervention: Reinfarction incidence
Number of subjects: 865
Study 17114657 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide 100 mg/m2 on days 1-3 and cisplatin 80 mg/m2 on day 1 with concurrent twice-daily thoracic radiotherapy (TRT) (1.5 Gy per fraction, total dose of 45 Gy) followed by irinotecan 60 mg/m2 on days 1, 8, and 15 and cisplatin 60 mg/m2 on day 1 of a 4-week cycle
Number of subjects: 51
Study 14618645 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide or Nedocromil (anti-inflammatory therapy)
Number of subjects: 41
Study 14618645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 14618645 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine
Number of subjects: 41
Study 10761282 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive questioning group
Number of subjects: 120
Study 10761282 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative questioning group
Number of subjects: 120
Study 10761282 — intervention group
Group type: COMPARATOR
Intervention: Control group (irrelevant issues)
Number of subjects: 120
Study 8796410 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. bolus of 1 g/kg of 25% albumin over 4 h, repeated after 24 and 48 h
Number of subjects: 37
Study 8796410 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous 24-h infusion of 1 g/kg of 25% albumin throughout the 60-h study period
Number of subjects: 37
Study 8796410 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 37
Study 1320259 — intervention group
Group type: EXPERIMENTAL
Intervention: ORG 2766 (20 mg, 4 capsules daily for six weeks)
Number of subjects: 3
Study 1320259 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 capsules daily for six weeks)
Number of subjects: 3
Study 3881948 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam 0.5 to 1 g twice daily
Number of subjects: 159
Study 3881948 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam 1 g three times daily
Number of subjects: 159
Study 3881948 — intervention group
Group type: COMPARATOR
Intervention: Cefamandole 1 g three times daily
Number of subjects: 159
Study 3881948 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam 1 to 6 g per day for eight days
Number of subjects: 159
Study 30964750 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengths-based case management over 6 months
Number of subjects: 349
Study 30964750 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 349
Study 30477732 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser photocoagulation
Number of subjects: 139
Study 30477732 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 139
Study 27456983 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitor monotherapy (80% darunavir, 14% lopinavir, 6% other)
Number of subjects: 290
Study 27456983 — intervention group
Group type: COMPARATOR
Intervention: Ongoing triple therapy
Number of subjects: 290